Welcome to our dedicated page for Optinose news (Ticker: OPTN), a resource for investors and traders seeking the latest updates and insights on Optinose stock.
Optinose Inc (OPTN) is a specialty pharmaceutical innovator focused on chronic sinusitis treatments through its patented Exhalation Delivery System. This page provides investors and healthcare professionals with essential updates on regulatory developments, clinical research, and corporate milestones.
Track key developments including FDA decisions, peer-reviewed study publications, and partnership announcements. Our curated news collection helps stakeholders monitor progress in ENT-focused drug-device combinations and chronic disease management innovations.
Find verified updates on XHANCE clinical trials, financial earnings reports, and market expansion strategies. All content undergoes strict editorial review to ensure accuracy and relevance for investment research and therapeutic advancement tracking.
Bookmark this page for timely updates on Optinose's novel approaches to nasal drug delivery and specialty pharmaceutical developments. Regularly refreshed content supports informed decision-making for investors and healthcare analysts alike.
Optinose (NASDAQ:OPTN) reported strong financial results for Q4 and full year 2024. XHANCE net revenue reached $22.4 million in Q4 2024 (up 13% YoY) and $78.2 million for full year 2024 (up 10% YoY).
The company experienced significant prescription growth, with Total Prescriptions (TRx) increasing 23% from Q3 to Q4 2024 (63,900 to 78,500) and New Prescriptions (NRx) rising 12% (25,600 to 28,700).
Notable achievements include the company's first-ever quarterly operating income of $0.4 million in Q4 2024. Operating expenses (SG&A plus R&D) totaled $87.3 million for 2024, up from $85.1 million in 2023. The company reported a net loss of $0.4 million ($0.04 per share) for Q4 and $21.5 million ($2.12 per share) for full year 2024. Cash position remained strong at $84.5 million as of December 31, 2024.
Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in ENT and allergy treatments, has announced the cancellation of its Q4 and full-year 2024 earnings conference call originally scheduled for March 20, 2025. The cancellation follows the company's earlier announcement of a definitive agreement to be acquired by Paratek Pharmaceuticals.
The acquisition deal is subject to shareholder approval and other customary closing conditions. Despite the earnings call cancellation, Optinose confirms it will still report its financial results for both the three-month and twelve-month periods ended December 31, 2024, in a timely manner.
Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in ENT and allergy treatments, has scheduled its Fourth Quarter and Full Year 2024 Financial Results announcement for March 20, 2025, before market open.
The company will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day, featuring the leadership team who will discuss financial results and corporate updates. Investors can access the webcast through Optinose's website investor section, while telephone participants must register in advance to receive dial-in details. A replay will be available on the company website for 60 days following the event.
Optinose (NASDAQ:OPTN) has announced preliminary unaudited XHANCE net product revenue of $22.4 million for Q4 2024. The company reported an estimated 20% sequential prescription growth rate from Q3 to Q4 2024.
CEO Ramy Mahmoud stated that the preliminary Q4 net product revenue aligns with their prior guidance and shows sustained growth in XHANCE prescriptions. The company plans to release full financial results and corporate updates in March.
The company notes that these preliminary results are subject to change pending completion of financial closing procedures, review adjustments, and other developments before the financial results are finalized.
Optinose (NASDAQ: OPTN) has announced a 1-for-15 reverse stock split effective December 30, 2024, at 5:00 p.m. EST. The company's common stock will trade on a split-adjusted basis starting December 31, 2024, under the same symbol 'OPTN' but with a new CUSIP number. This strategic move aims to regain compliance with Nasdaq's $1.00 minimum closing bid price requirement.
The reverse split will reduce outstanding shares from 150,829,507 to approximately 10,055,300. All outstanding options, warrants, and shares reserved for future issuance will be proportionally adjusted. Stockholders will receive cash for any fractional shares based on the closing price on December 30, 2024. The split was approved by stockholders on December 23, 2024, and will not affect stockholders' ownership percentages.
Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in ear, nose and throat (ENT) and allergy treatments, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's management team will deliver a company overview and business update on December 5, 2024, at 1:30 p.m. ET. The presentation will be accessible via webcast on the Investors page of the Optinose website, with replay availability for 30 days after the event.
Optinose (NASDAQ:OPTN) reported Q3 2024 financial results with XHANCE net revenue of $20.4 million, up 3% from Q3 2023. The company observed a positive inflection in new prescriptions starting September, with October showing a 20-40% increase in weekly new prescriptions. However, the company decreased its full-year 2024 XHANCE net revenue guidance to $75.0-79.0 million from previous $85.0-90.0 million. Operating expenses guidance was reduced to $90.0-93.0 million. The company reported Q3 net income of $0.5 million, while maintaining cash and cash equivalents of $82.5 million as of September 30, 2024.
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on ENT and allergy specialists, has scheduled its third quarter 2024 financial results announcement for Tuesday, November 12, 2024, before market open. The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring its leadership team who will discuss financial results and corporate updates. Interested participants can join via webcast through the company's investor relations website or register for telephone access. A replay will be available for 60 days following the event.
Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in ENT and allergy treatments, has appointed Terry Kohler as Chief Financial Officer. Kohler, previously CFO at Verrica Pharmaceuticals, brings over 20 years of biotech finance experience. CEO Ramy Mahmoud emphasized Kohler's expertise in financial strategy for commercial-stage branded pharmaceuticals, which will be valuable for maximizing XHANCE's potential in treating chronic rhinosinusitis.
Kohler expressed enthusiasm about joining Optinose during XHANCE's transition towards a new indication with significant potential. His background includes roles at Endo International PLC and participation in Johnson & Johnson's MBA Leadership Development program. As part of his appointment, Kohler received a non-qualified stock option for 675,000 shares at $0.71 per share and 150,000 restricted stock units, subject to vesting conditions.
Optinose (NASDAQ:OPTN) announced the peer-reviewed publication of a paper in the International Forum of Allergy & Rhinology, highlighting the benefits of XHANCE in chronic rhinosinusitis (CRS) patients. The study, based on two 24-week randomized trials (ReOpen1 and ReOpen2), evaluated XHANCE versus EDS-placebo in CRS patients with and without prior sinus surgery.
Key findings include:
- XHANCE improved symptoms, sinus opacification, and quality of life in both groups
- Previous surgery is not required for CRS patients to benefit from XHANCE
- XHANCE can be helpful for patients even after surgery
The Exhalation Delivery System™ with fluticasone (EDS-FLU; XHANCE) creates unique biomechanics that enable deposition of corticosteroid into sinuses and sinus drainage pathways, proving effective for treating chronic sinusitis without nasal polyps.
FAQ
What is the current stock price of Optinose (OPTN)?
What is the market cap of Optinose (OPTN)?
